gemcitabine and cisplatin

Phase 3Small molecule

FForma Therapeutics, Inc.

gemcitabine and cisplatin is one of 243 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

242

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Bladder CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

gemcitabine and cisplatin

FForma Therapeutics, Inc.

Phase 3

2 2

Byetta

AstraZeneca

Preclinical

1 3

MS Contin

Merck & Co.

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Chemotherapy Agents

Takeda

Preclinical

1 6

Active Comparator

Moderna

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Unresectable Biliary Tract Carcinoma

NCT06749730

Q3 2027

Phase 2Not yet recruiting

Bladder Cancer

NCT07184021

Q4 2027

Phase 3Recruiting

Cholangiocarcinoma

NCT05823311

Q3 2028

Phase 2Recruiting

Cholangiocarcinoma

NCT05532059

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma8 trials

Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Completed·SSun Yat-sen University·Phase 3·NCT01528618·362 enrolled

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Unknown status·SSun Yat-sen University·Phase 1·NCT04073784·41 enrolled

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Completed·—·Phase 2·NCT01596868·60 enrolled

Show 5 more trials

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT03840421·468 enrolled

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT01915134·362 enrolled

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT01872962·480 enrolled

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT05979961·454 enrolled

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·N/A·NCT02627807·386 enrolled

Bladder Cancer4 trials

Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Completed·—·Phase 3·NCT01734798·198 enrolled

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Recruiting·FFudan University·Phase 2·NCT05531123·30 enrolled

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01589094·51 enrolled

Show 1 more trial

Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

Not yet recruiting·—·Phase 2·NCT07184021·30 enrolled

Cholangiocarcinoma3 trials

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05532059·100 enrolled

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Terminated·EEpicentRx, Inc.·Phase 2·NCT02452970·4 enrolled

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05823311·80 enrolled

Pancreatic Cancer2 trials

Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer

Completed·SSeoul National University Hospital·Phase 2·NCT01396681·70 enrolled

Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05182112·1 enrolled

Chemotherapy1 trial

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Unknown status·SShi Ming·Phase 3·NCT04961970·188 enrolled

9 more indications

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer

Withdrawn·LLahey Clinic·Phase 2·NCT00696007

Urothelial Carcinoma1 trial

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01261728·57 enrolled

Unresectable Biliary Tract Carcinoma1 trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06749730·63 enrolled

Stereotactic Body Radiotherapy1 trial

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled

Cervical Cancer1 trial

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Unknown status·CChuangzhen Chen·Phase 3·NCT05189028·290 enrolled

Advanced Solid Tumors1 trial

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Unknown status·HHutchison Medipharma Limited·Phase 1/2·NCT05173142·141 enrolled

Combination Therapy1 trial

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Completed·FFudan University·Phase 2·NCT00601159·70 enrolled

Glioma1 trial

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Completed·FForma Therapeutics, Inc.·Phase 1/2·NCT03684811·93 enrolled

Concurrent Chemoradiotherapy1 trial

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Unknown status·CChaosu Hu·Phase 3·NCT03366415·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for gemcitabine and cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine and cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine and cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forma Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForma Therapeutics, Inc.

gemcitabine and cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma8 trials

Bladder Cancer4 trials

Cholangiocarcinoma3 trials

Pancreatic Cancer2 trials

Chemotherapy1 trial

Neoadjuvant Chemotherapy1 trial

Urothelial Carcinoma1 trial

Unresectable Biliary Tract Carcinoma1 trial

Stereotactic Body Radiotherapy1 trial

Cervical Cancer1 trial

Advanced Solid Tumors1 trial

Combination Therapy1 trial

Glioma1 trial

Concurrent Chemoradiotherapy1 trial

References

Drug Info

Quick Facts

Related News